We’re a clinical-stage drug platform company focused on treating neuroinflammation.

Originally from Halmstad, Sweden, Christer Rosén is the primary founder and Chairman & CEO of Jupiter Neurosciences, Inc.. His background and education as a programmer and system analyst gives him a solution minded mentality and an expert in building companies with strong and dedicated people. He started his first company at the age of 17, a discotheque opened only on the weekends not to disturb study times. After college he started a software consulting company as well as buying a few restaurants and a hotel continuing the involvement in the entertainment business. In 1983, Mr. Rosén and his family decided to leave Sweden and moved to Florida in search of new ventures to be involved in. After purchasing a Jeep Wrangler, he invented the “Soundbar”, speaker system fastened to the overheard roll bar, became a Jeep supplier and received supplier of the year awards in 1995 and 1996. The company, Top Source Technologies where he was President, went public on the American Stock Exchange and was later bought by a PE firm. Afterwards, Mr. Rosén started EffRx Pharmaceuticals in 1997, where he served as Chairman & CEO for 17 years.. EffRx was started as a vitamin company, but with the addition of Marshall Hayward, Jupiter Neurosciences CSO, invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto®. Binosto® is distributed in several parts of the world and gave Mr. Rosén a successful and full insight in all the aspects of pharmaceutical development, regulatory paths and distribution.

Saleem Elmasri, CPA has been Chief Financial Officer since January 2023. Mr. Elmasri has been working at Titan Advisory Services LLC as Principal since September 2020. Titan Advisory Services LLC is a boutique advisory firm focused on providing collaborative and customized financial operations and CFO services to early stage companies. Mr. Elmasri was Managing Director at DLA LLC, a professional services firm providing clients internal audit, accounting advisory, and corporate finance services, from June 2019 to April 2021 (ended full time employment September 2020 and became a consultant to DLA through April 2021). Prior to that, Mr. Elmasri worked as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm, from March 2018 to June 2019, and worked as Senior Manager for PricewaterhouseCoopers LLP, a Big-4 Accounting and Global Professional Services firm, from September 2007 to March 2018. Mr. Elmasri is a CPA and seasoned business professional who has a passion for delivering meaningful and measurable value to clients through practical solutions. Mr. Elmasri has over 15 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers and worked on several of the firm’s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, Mr. Elmasri transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting advisory. Mr. Elmasri has B.S. degrees in Accounting and Finance from Rutgers University.

Marshall Hayward is the Chief Scientific Officer at Jupiter Neurosciences, Inc. Between 2002-2013, Dr. Hayward served as Chief Scientific Officer at Effrx Pharmaceuticals where he was instrumental in all aspects of the development and approvals of the Binosto® product. He also served as Vice President of Business Development for Hurley Consulting Associates, LTD., a specialist pharmaceutical consulting firm, and was previously Director of New Business Development at Rhoda Pharmaceutical Ingredients. Dr. Hayward was also the Director and Vice President of Analgesics Research and Development at SmithKline Beecham (UK). He was a senior scientist in wound healing research and development at Johnson & Johnson. His pharmaceutical experience began at Ayerst Laboratories Research (later Wyeth), responsible for metabolic bone disease research. Dr. Hayward received a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and did postdoctoral work there in molecular biology. His undergraduate degree is a B.S. (Biochemistry with High Honor) from the Honors College of Michigan State University. In total, Dr. Hayward has over 30 years of industry R&D experience.

Alexander Rosén is a Co-Founder and Chief Administrative Officer at Jupiter Orphan Therapeutics, Inc and has been with the Company since its inception. From February 2019 to July 2021, Mr. Rosén worked part time as Controller as well as Head of Administration & Office Management at X-VAX Technology, Inc. Prior to his time in the corporate world, Mr. Rosén played professional golf traveling all over North America and Europe playing on various tours such as the PGA Tour Canada, Nordea, and ECCO Tours. Mr. Rosén graduated from Halmstad University in 2012.

Dr. Wahlestedt, MD, Ph.D. is the Consulting Chief Medical Officer at Jupiter Neurosciences. He is a native Swede, obtaining his MD and PhD degrees from Lund University. Dr. Wahlestedt is a renowned scientist throughout the pharmaceutical industry. He is presently the Leonard M. Miller Professor & Associate Dean for Therapeutic Innovation at the University of Miami Miller School of Medicine. Between 2005-2011 Dr. Wahlestedt was the founding professor and Director of Neuroscience at The Scripps Research Institute in Florida. Before that, Dr. Wahlestedt was the Professor and Department Chair at Karolinska Institute in Stockholm, Sweden from 1997-2005. He has previously been a faculty member at Cornell University Medical College as well as at McGill University. Dr. Wahlestedt has also spent more than a decade directing R&D teams for Astra-Zeneca and Pharmacia/Pfizer. Along with all of Dr. Wahlestedt's pharmaceutical ventures, he has also co-founded 3 biotech companies.

Shaun P Brothers, Ph.D. is the Consulting VP of Scientific Research at Jupiter Neurosciences. Dr. Brothers is presently the Assistant Professor at the University of Miami and Associate Director at Center for Therapeutic Innovation. He was formerly a researcher at Scripps Research Institute in Jupiter, Florida. He previously co-founded 2 biotech companies. Dr. Brothers is an expert reviewer for molecular probes and drug discovery in neuroscience NIH study sections.

Alison D. Silva is the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.

Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison obtained her undergraduate degree from Clark University and her graduate degree from the University of Massachusetts Medical Center

Dr. Wahlestedt, MD, Ph.D. is the Consulting Chief Medical Officer at Jupiter Neurosciences. He is a native Swede, obtaining his MD and PhD degrees from Lund University. Dr. Wahlestedt is a renowned scientist throughout the pharmaceutical industry. He is presently the Leonard M. Miller Professor & Associate Dean for Therapeutic Innovation at the University of Miami Miller School of Medicine. Between 2005-2011 Dr. Wahlestedt was the founding professor and Director of Neuroscience at The Scripps Research Institute in Florida. Before that, Dr. Wahlestedt was the Professor and Department Chair at Karolinska Institute in Stockholm, Sweden from 1997-2005. He has previously been a faculty member at Cornell University Medical College as well as at McGill University. Dr. Wahlestedt has also spent more than a decade directing R&D teams for Astra-Zeneca and Pharmacia/Pfizer. Along with all of Dr. Wahlestedt's pharmaceutical ventures, he has also co-founded 3 biotech companies.

Co-Chairman of the Scientific Advisory Board at Jupiter Neurosciences, Inc. Rudolph Tanzi Ph.D, is the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990. In his research achievements, Dr. Tanzi served on the team that was the first to find a disease gene ((Huntington’s disease) using human genetic markers, helping to launch the field of neurogenetics. He later co-discovered all three early-onset familial Alzheimer’s disease genes and identified several others as leader of the Cure Alzheimer’s Fund Alzheimer’s Genome Project. He also co-discovered the Wilson’s disease gene and several other neurological disease genes. Most recently, he and his team used Alzheimer’s genes and human stem cells to create what the New York Times coined, “Alzheimer’s-in-a-Dish”. This is a three-dimensional human stem cell-derived neural culture system that is considered to be the first true model of Alzheimer’s disease, recapitulating both pathological hallmarks of Alzheimer’s disease: plaques and tangles. The model has made drug screening for Alzheimer’s disease 10 times cheaper and 10 times faster. Dr. Tanzi has developed novel therapeutics for AD including gamma secretase modulators and metal chaperones (PBT; Prana) aimed at lowering plaque and tangle pathology. Both have been entered into clinical trials for Alzheimer’s patients. Dr. Tanzi is also very active in the areas of integrative medicine and applications to brain health. In this regard, along with Dr. Deepak Chopra, Dr. Tanzi co-directs the Self-Directed Biological Transformation Initiative (SBTI) aimed at exploring and quantifying the effects of lifestyle interventions on neuroplasticity and epigenetics.

Dr. Tanzi has published over 500 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, and many others. He was named to TIME magazine’s 2015 list of TIME100 Most Influential People in the World, and received the Smithsonian American Ingenuity Award, the top national award for invention and innovation. He co-authored the popular trade books “Decoding Darkness”, New York Times best seller, “Super Brain”, and international best seller “Super Genes” with Dr. Deepak Chopra. He was named by GQ magazine as a Rock Star of Science, and in his spare time, has played keyboards with the band Aerosmith. With singer, Chris Mann, he also composed the beautiful ballad, “Remember Me”, which honors Alzheimer’s patients, and is being used to raise funds for Alzheimer’s research at the Cure Alzheimer’s Fund, for which, Dr. Tanzi serves as Chair of the Cure Alzheimer’s Fund Research Consortium.

Professor Li- Huei Tsai, Ph.D., is a Scientific Advisor at Jupiter Neurosciences. She currently is the Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology, a Picower Professor of Neuroscience, and an Associate Member of the Broad Institute. She obtained Ph.D. from University of Texas Southwestern Medical Centre in Dallas and postdoctoral training at Cold Spring Harbor Laboratories and Massachusetts General Hospital. Dr. Tsai became Assistant Professor of Pathology at Harvard Medical School and was promoted to tenure Professor at Harvard in 2002. She relocated to Massachusetts Institute of Technology in 2006. She was an Investigator of the Howard Hughes Medical Institute from 1997 to 2013. Dr. Tsai is also a Fellow of the American Association for the Advancement of Science, a member of the National Academy of Medicine, and an Academician of the Academia Sinica in Taiwan. http://www.tsailaboratory.mit.edu

Raymond Scott Turner, MD, Ph.D., is a Scientific Advisor at Jupiter Neurosciences. He is currently the Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC. Previously, he was Chief of the Neurology Service at the VA Ann Arbor Healthcare System and Associate Professor and Associate Chair in the Department of Neurology, University of Michigan. Turner obtained his MD and Ph.D. degrees from Emory University, Atlanta, and completed his internship, residency, and fellowship at the University of Pennsylvania, Philadelphia. He was recruited to Georgetown in 2008. Dr. Turner has received numerous prestigious awards, including a fellowship from the Howard Hughes Medical Institute and a Paul Beeson Scholarship. Dr. Turner serves as a reviewer for granting agencies and biomedical journals, has published more than seventy peer-reviewed paper, editorials, and book chapters, as well as lectures widely. He is board- certified in Psychiatry and Neurology.

Charbel Moussa, MBBS, PH.D., is an Associate Professor of Neurology

Director- Laboratory for Dementia and Parkinsonism

Scientific and Clinical Research Director- Translational Neurotherapeutics Program National Parkinson’s Foundation Center

Director- Lewy Body Dementia Research Center of Excellence Department of Neurology, Georgetown University Medical Center

Director- Neurosciences Grand Rounds Georgetown University Medical Center

Peter Elliott, Ph.D., is a Scientific Advisor at Jupiter Neurosciences, Inc. Mr. Elliott holds a B.Sc. in Pharmacology from London University and a Ph.D. in Psychopharmacology from Cambridge University, After post-docs at Duke, Yale and McGill, Mr. Elliott moved back to the UK to join Glaxo Group Research. During his 5 years there he led a number of CNS programs focusing on movement disorders, neurodegeneration as well as pain. Peter moved back to the USA to enter biotech at Alkermes in Cambridge, MA, as Director of Pharmacology. After that he moved on to ProScript which was acquired by LeukoSite, and ultimately Millennium. Mr. Elliott was Vice President of Pharmacology and Development during this time and was a co-developer of the multiple myeloma drug, Velcade© and PS-519 for stroke. He later moved on to join CominatoRx where he was Executive Vice President of Product Development and led the efforts resulting in 8 phase II programs in inflammation and oncology. Peter was then Senior Vice President of R&D at Sirtris Pharmaceuticals. As part of work from his teams, three SIRT1 activators entered clinical development, SRT501, SRT2104 and SRT2379. He was also an integral part of the road-show to take Sirtris public with a successful IPO in 2007, leading to it being purchased by GSK in 2008 for $720M. Subsequently, Peter has acted as a consultant to the industry.

Dr. Dalton Dietrich is Scientific Director at The Miami Project to Cure Paralysis and the Kinetic Concepts Distinguished Chair in Neurosurgery at the University of Miami Miller School of Medicine. He received his Ph.D. in Anatomy from the Medical College of Virginia in 1979 and completed a postdoctoral fellowship in the Department of Pharmacology at Washington University, St. Louis, MO, 1981.

Dr. Dietrich has published over 375 refereed journal articles, 75 book chapters and 4 books. His published work has been cited over 38,000 times. He has been listed by the Institute of Scientific Information as a “Highly Cited Researcher”, placing him in the top 0.5% of all scientists based on the impact his research has made on other scientists. Dr. Dietrich has been a thesis/dissertation advisor to 9 graduate students and has trained over 50 postdoctoral fellows and visiting scholars from all over the world. His research programs are supported by the NIH, Department of Defense, Veteran’s Administration, State of Florida and The Miami Project to Cure Paralysis. He serves on many study sections for NIH, Department of Defense, Veteran’s Administration, and several Editorial Boards. He is currently Editor-in-Chief of the Journal Therapeutic Hypothermia & Temperature Management and Deputy Editor of the Journal of Neurotrauma. Dr. Dietrich is a founding member of InflamaCore and ACESO Therapeutics.

Mr. Wiinberg is an experienced healthcare industry professional who has served on the boards of several healthcare industry associations. At Wyeth, he has been both President of the Global consumer health care business and President of the European pharma business. He also held the position of CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical company UCB. He is also chairman of the board of Sigrid Therapeutics AB, Chairman of the Board at Hansa Biopharma as well as CEO and chairman of the board of Ulf Wiinberg Consulting & Invest AB.

Mr. Kirsch is a Senior Advisor and Head of Healthcare at GCA Global, an investment bank providing strategic M&A, capital markets and private funds advisory services to growth companies and market leaders. From 1994 to 2004, Mr. Kirsch was Global Head of Healthcare Research, with more than 200 companies under coverage, and later served as Head of Capital Markets at Vector Securities, a healthcare investment banking boutique that was later acquired by Prudential Securities. From 1990 to 1993, Mr. Kirsch was Chief Executive Officer of NatWest Markets, currently the investment banking arm of The Royal Bank of Scotland Group. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert, where he served as Executive Vice President of the Global Equity Division, a member of the Executive Committee and notably was a #1-ranked Institutional Investor research analyst.

Mr. Kirsch serves on the Board of Directors of Liquidia Technologies, Inc., as well as Kadmon Pharmaceuticals.. He previously served on the Board of Directors of Immunomedics, a public biopharmaceutical company, where he also served on the Audit Committee. Mr. Kirsch serves as Chairman of the Board of Directors at Aralez, Inc., a publicly traded biopharmaceutical company, where he is also Chair of the Audit Committee. Mr. Kirsch received his B.A. in Finance from the University of Rhode Island and his MBA in Finance from Bernard M. Baruch College

John Ditton is an accomplished Senior Executive, Consultant, and Board Member with more than 35 years of success across the biotechnology, pharmaceutical, healthcare, managed care, and rehabilitation industries. Leveraging extensive experience leading technology, marketing, and social media, designing and implementing systems, he is a valuable advisor for an organization looking to utilize technology, analyze databases to enhance patient delivery and care, or improve medical device offerings. His broad areas of expertise include commercial planning and business development, patient relations, market research and analysis, product launch, and ultra-orphan drug development and product management. Throughout his executive career, John has held leadership positions with Rare Connections, Ultragenyx Pharmaceutical Inc., and The EveryLife Foundation for Rare Disease.

Mr. Dant, EveryLife Foundation for Rare Diseases Board Chair, is a parent advocate and retired Carrolton, Texas Police Department Chief of Police. Mark and his wife Jeanne are the parents of Ryan, who is 33 years old and the longest treated person in the world with MPS I. Mark and Jeanne spearheaded the funding for the first MPS Enzyme Replacement Therapy, Aldurazyme, through their Foundation, the Ryan Foundation. In partnership with Dr. Emil Kakkis, Mr. Dant and his family were also key advocates speaking to the FDA about the importance and significant impact of ERT for the treatment of mucopolysaccharidoses. In 2009, Mr. Dant and his family successfully championed Congress to pass the Ryan Dant Health Care Opportunity Act, H.R. 1441-111.

Nicholas H. Hemmerly has been a Managing Partner and Head of Investment Banking for Bridgeway Capital Partners LLC (“Bridgeway”) since February 2020. Mr. Hemmerly has over 18 years of investment banking experience with broad transactional experience having completed approximately $25 billion of debt and equity transactions. Prior to joining Bridgeway from March 2016 to February 2020, Mr. Hemmerly was the Director, Head of Life Sciences at PricewaterhouseCoopers LLC (“PwC”) where he led U.S. M&A and capital raising in the life sciences space with a focus on specialty and generic pharmaceuticals as well as healthcare consumer products and contract manufacturing. Prior to PwC from June 2014 to March 2016, Mr. Hemmerly was a Vice President at Jefferies LLC with a focus on executing M&A and financing transactions within the pharmaceutical and life sciences sectors. Prior experience includes investment banking roles in JPMorgan Chase & Co.’s Healthcare Group as well as JMP Securities LLC’s Healthcare Group. Mr. Hemmerly began his investment banking career as an analyst with Wachovia Securities. During his career, Mr. Hemmerly has completed over six billion dollars in M&A and capital raising transactions.

Julie Kampf is a global business executive and thought leader on talent and diversity, with 30 years of experience in the life science and retail/consumer fashion industries and on not-for-profit Boards of Directors. She is currently Board Director for Marizyme, Inc. a Florida-based Biotech Company, and Chief Executive Officer of JBK Associates International, which she founded in 2003, which has grown to become a multi-million-dollar company as one of INC’s fastest growing private companies, four consecutive years, beginning in 2011. Julie has a reputation for delivering results that exceed expectations working with life science company CEOs and Boards, ranging from companies included in the Fortune 100 to early stage start-up companies.

Prior to founding JBK and moving into the life science industry, Julie gained deep business knowledge in product development, marketing, sales, and organizational development, having started her 17-year career in the fashion industry as a Macy’s Executive Trainee, with a subsequent series of roles of increasing responsibility at Warnaco Inc, Hartmann Inc and Michael Stevens, LTD, ultimately rising to Sr. VP with P&L responsibilities with a track record of consistently growing revenues and delivering strong profits.

In addition to recent public board experience, Julie has significant not-for-profit board and advisory committee experience having served on Howard University’s School of Communications Board of Visitors, where she helped launch an entrepreneurial incubator and established an award for student entrepreneurs. Her not-for-profit board service spans the Linkage Diversity Summit, Enterprising Women magazine, International Association of Corporate and Professional Recruitment, Girl Scout Council of Bergen County, Guiding Eyes for the Blind. Additionally, she has served on the Executive Committee of Good Grief, a national leader in delivering grief services to children and their families.

Deeply committed to enhancing the careers and well-being of other women, Julie was president of the 1,750-member HBA (Healthcare Businesswomen’s Association) Metro Chapter, where she co-founded a successful mentoring program. At the same time as a founding member of Bergen County’s Women United in Philanthropy, she helped launch the area’s largest grantor giving circle focused on women’s issues.

Julie has received numerous awards, including having been recognized as one of New Jersey’s Best 50 Women in Business, an Enterprising Woman of The Year, , an Ernst & Young Entrepreneurial Winning Woman and a Brava Smart CEO Winner. In 2013 and 2009, Julie was recognized as one of the PharmaVoice 100 ‘most inspiring people in the Life Science Industry’.

As a thought leader, Julie has spoken at the Yale School of Management to the Multicultural Forum on Workplace Diversity, published articles on talent-related issues, appeared on national TV and other media outlets, and has authored a book on how to stand up for principles such as quality, integrity and service.

Julie earned a BA in Political Science from the University of Rhode Island, where she minored in Marketing. Outside of work, she enjoys golfing and international travel with her husband.

Experienced life science executive and entrepreneur with demonstrated ability to lead cross functional team of experts to develop emerging healthcare technologies. Ability to leverage broad managerial, operational, research and financial experience to achieve results in organizations backed by private investors, venture capital, private equity and/or corporate industry partners.

Experienced life science executive and entrepreneur with demonstrated ability to lead cross functional team of experts to develop emerging healthcare technologies. Ability to leverage broad managerial, operational, research and financial experience to achieve results in organizations backed by private investors, venture capital, private equity and/or corporate industry partners.

For over 25 years, Allison W. Brady has been a passionate fundraiser and advocate for rare diseases medical research and patients.

She serves on the board of Gene Spotlight, Inc., a non-profit dedicated to raising money to sponsor medical research for rare diseases. She has organized fundraising events for the charity through Give Miami Day, De Beers (jewelry store), Ann Taylor (clothing store), online charity auctions with Miley Cyrus, Keith Urban, Miami Marlins via CharityBuzz to raise funds for Gene Spotlight. She co-runs an annual bike team for Team Gene Spotlight to raise funds for the Million Dollar Bike Ride with Penn Medicine to fund research grants. Gene Spotlight is the largest outside investor in Jupiter orphan Therapeutics, Inc.

Her fundraising efforts for rare diseases began with gala events she organized called “Songs for Sophia” with performances by opera’s finest including Placido Domingo, Denyce Graves, Bryn Terfel, and Frederica von Stade. The money raised from those events supported medical research for a rare bone disease known as FOP.

She also worked with the press outreach, including having the Associated Press cover these events, which led to them following the scientific and medical progress of FOP for over a decade as new techniques using shark cartilage were developed and the FOP gene was discovered at CHOP by Dr. Fred Kaplan at UPENN. In part, due to her success in fundraising and awareness of FOP, in 2007, Allison was the sole recipient of the University of Pennsylvania’s Young Alumni of the Year Award.

She actively supports several other medical based charities including EveryLife Foundation for Rare Diseases, Jackson Health Foundation, Penn Medicine, Mount Sinai Miami Beach, Mount Sinai New York City, Kids Hear Now, Nicklaus Children’s Hospital, Sabrina Cohen Foundation, United HomeCare Services, and more.

25 years in biotechnology, pharmaceutical, medical device and healthcare commercial planning & business development. Successful U.S. and ROW product launch, and market expansion campaigns. Senior management background in marketing, business development and new product planning, with strong strategic planning and sales assets developed as a leader of commercial teams. C-level consulting experience. Broad knowledge of digital marketing & social media.